TY - JOUR
T1 - Two-Year Duration of Immunity of Inactivated Poliovirus Vaccine
T2 - A Follow-up Study in Pakistan in 2020
AU - Saleem, Ali Faisal
AU - Parkar, Sadia
AU - Zehra, Syeda Mahjabeen
AU - Kazi, Zaubina
AU - Pethani, Asma
AU - Zhang, Yiting
AU - Mainou, Bernardo A.
AU - Lopez Cavestany, Rocio
AU - MacKlin, Grace
AU - Jeyaseelan, Visalakshi
AU - Mach, Ondrej
N1 - Publisher Copyright:
© 2023 The Author(s). Published by Oxford University Press on behalf of Infectious Diseases Society of America. All rights reserved.
PY - 2024/1/15
Y1 - 2024/1/15
N2 - This was a follow-up study conducted in 2020 assessing changes in levels of type 2 poliovirus-neutralizing antibodies 2 years postimmunization in children who received inactivated poliovirus vaccine (IPV) in Karachi, Pakistan. Unexpectedly, the findings revealed an increase in seroprevalence of type 2 antibodies from 73.1% to 81.6% 1 year and 2 years after IPV, respectively. The increase in type 2 immunity could result from the intensive transmission of circulating vaccine-derived poliovirus type 2 (cVDPV2) in Karachi during the second year of IPV administration. This study suggests that the cVDPV2 outbreak detected in Pakistan infected large proportions of children in Karachi.
AB - This was a follow-up study conducted in 2020 assessing changes in levels of type 2 poliovirus-neutralizing antibodies 2 years postimmunization in children who received inactivated poliovirus vaccine (IPV) in Karachi, Pakistan. Unexpectedly, the findings revealed an increase in seroprevalence of type 2 antibodies from 73.1% to 81.6% 1 year and 2 years after IPV, respectively. The increase in type 2 immunity could result from the intensive transmission of circulating vaccine-derived poliovirus type 2 (cVDPV2) in Karachi during the second year of IPV administration. This study suggests that the cVDPV2 outbreak detected in Pakistan infected large proportions of children in Karachi.
KW - Pakistan
KW - duration of immunity
KW - inactivated poliovirus vaccine
KW - poliovirus
KW - seroprevalence
UR - http://www.scopus.com/inward/record.url?scp=85182501514&partnerID=8YFLogxK
U2 - 10.1093/infdis/jiad237
DO - 10.1093/infdis/jiad237
M3 - Article
C2 - 37368349
AN - SCOPUS:85182501514
SN - 0022-1899
VL - 229
SP - 39
EP - 42
JO - Journal of Infectious Diseases
JF - Journal of Infectious Diseases
IS - 1
ER -
